Enliven Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ELVN | AVBP | TNGX | IDYA | 9966.HK | SNDX | |
|---|---|---|---|---|---|---|
| Market cap | 3.46B | 665.16M | 3.91B | 3.12B | 6.43B | 940.80M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -20.4 | -3.6 | -13.8 | -7.9 | -21.0 | -14.4 |
| Price/book | 3.9 | 1.8 | 3.8 | 2.9 | 3.3 | -54.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +158.20% | −26.64% | +189.39% | +8.41% | −39.84% | −28.86% |
| Today | +5.40% | +3.61% | +0.04% | +3.29% | +1.68% | −26.87% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ELVN news ›Enliven Therapeutics (NASDAQ:ELVN) CFO Sells $231,572.64 in Stock
Posted by Danessa Lincoln on Oct 24th, 2026 Benjamin Hohl also recently made the following trade(s): NASDAQ ELVN opened at $41.52 on Friday. The firm’s 50 day moving average price is $50.26 and its 200-day moving average price is $47.98.…
Enliven Therapeutics director sells 13,000 shares
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting Lithium Africa Receives Two Non-Binding Offers to Fund the Springbok Project, Including a US$60…
Enliven Therapeutics appoints Kristine Ball director
Ball’s options vest in 1/36th increments on each monthly grant anniversary, subject to continued service, and vest in full upon a Change in Control. Enliven said it remains focused on initiating the pivotal Phase 3 ENABLE-2 trial of…
Enliven Therapeutics director plans $560K share sale
Director Helen Collins plans to sell 15,000 Enliven Therapeutics (ELVN) shares. Stock Titan Enliven Therapeutics director plans $560K share sale The proposed sale is identified as being under a Rule 10b5-1 plan adopted October 19, 2025.…
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its price target boosted by research analysts at HC Wainwright from $65.00 to $73.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the…
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
PR Newswire Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage d
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
Stay updated with Business News This Week – your source for the latest business news weekly, market updates, and top business stories Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 7, 2026…
Enliven Therapeutics to Present at Upcoming Investor Conferences
Sep 03, 2026, 16:05 ET BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small…
Enliven Therapeutics (ELVN) Gets FDA Alignment on ENABLE-2 Phase 3 Design
TradingView Enliven Therapeutics (ELVN) Gets FDA Alignment on ENABLE-2 Phase 3 Design Enliven Therapeutics announced FDA alignment on the ENABLE-2 Phase 3 trial design for relcobatinib (ELVN-001) in previously treated chronic
Enliven Therapeutics grants Ball 23,394 options
Enliven Therapeutics (Nasdaq: ELVN) is a Boulder-based clinical-stage biopharmaceutical company developing small molecule precision oncology therapies. - [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity Enliven Therapeutics…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net5
- defenseworld.net2
- prnewswire.com2
- businessnewsthisweek.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.